Showing 2581-2590 of 3039 results for "".
- Nicox’s NCX 4251 Mississippi Phase 2b Blepharitis Trial Reaches 50% Enrollmenthttps://modernod.com/news/nicoxs-ncx-4251-mississippi-phase-2b-blepharitis-trial-reaches-50-enrollment/2479109/Nicox SA announced that 102 patients in the NCX 4251 Mississippi phase 2b blepharitis clinical trial have now been randomized out of a target of 200, with topline results currently on track to be announced during Q4 2021. “Achievement of 50% enrollment in this phase 2b trial of NCX 4251 in
- Ora Appoints David P. Bingaman, DVM, PhD, in Newly Created Chief Development Officer Positionhttps://modernod.com/news/ora-appoints-david-p-bingaman-dvm-phd-in-newly-created-chief-development-officer-position/2479097/Ora announced that David P. Bingaman, DVM, PhD, D. ACVO has joined the company in a newly created role of Chief Development Officer (CDO). Dr. Bingaman will oversee clinical and nonclinical activities that directly impact Ora’s customers around the world. Ora’s clinical research spans all
- Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of Investigational Glaucoma Drug QLS-101https://modernod.com/news/qlaris-bio-enrolls-first-patient-in-phase-1-2-studies-of-investigational-glaucoma-drug-qls-101/2479081/Qlaris Bio announced the enrollment of the first patient in the phase 1/2 clinical program for QLS-101, an investigational therapy designed to lower IOP by reducing episcleral venous pressure (EVP) in individuals with glaucoma. QLS-101 is a novel adenosine triphosphate (ATP)-sensitive pota
- National Optometric Association to Host Regional Meeting at Vision Expo East 2021https://modernod.com/news/national-optometric-association-to-host-regional-meeting-at-vision-expo-east-2021/2479076/The Vision Council and Reed Exhibitions, organizers of Vision Expo, announce that the National Optometric Association (NOA), an organization dedicated to advancing the visual health of minority populations through the delivery of effective and efficient eye and vision ca
- Santen Announces Global Research Initiative to Study and Develop New Treatments for Glaucomahttps://modernod.com/news/santen-announces-global-research-initiative-to-study-and-develop-new-treatments-for-glaucoma/2479067/Santen announced a research initiative with scientists from Massachusetts Eye and Ear, and Ulster University, UK, to research and develop novel treatments for glaucoma. The aim
- Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathyhttps://modernod.com/news/ocuphire-initiates-zeta-1-phase-2-clinical-trial-investigating-apx3330-in-diabetic-retinopathy/2479060/Ocuphire Pharma announced that it has screened the first patient in ZETA-1, a phase 2 trial to evaluate APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (PDR). Effects on diabetic macular edema will be explored as a secondary outcome. A number o
- FDA Approves Rayner’s RayOne EMV IOLhttps://modernod.com/news/fda-approves-rayners-rayone-emv-iol/2479019/Rayner’s RayOne EMV fully preloaded non-diffractive IOL has received FDA approval. RayOne EMV was developed in collaboration with renowned surgeon Professor Graham Barrett, president of the Australasian Society of Cataract & Refractive Surgeons. Dr. Mariano Royo, Director
- NeurOptics Launches Pupillometry Program at Vanderbilt University Medical Centerhttps://modernod.com/news/neuroptics-launches-pupillometry-program-at-vanderbilt-university-medical-center/2479015/NeurOptics recently announced that its NPi-200 pupillometers and the Neurological Pupil Index (NPi) are now being used in the Neurological Intensive Care Unit at Vanderbilt University Medical Center, in Nashville, Tennessee, as an important measurement for managing patients with brain injury.
- ProQR Announces Positive Results From Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trialshttps://modernod.com/news/proqr-announces-positive-results-from-clinical-trial-of-qr-421a-in-usher-syndrome-and-plans-to-start-pivotal-trials/2479006/ProQR Therapeutics announced results from a planned analysis of its phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. In the trial, QR-421a demonstrated benefit on multiple measures of v
- Nicox’s NCX 470 Mont Blanc Phase 3 Glaucoma Trial Reaches 50% Enrollment Milestonehttps://modernod.com/news/nicoxs-ncx-470-mont-blanc-phase-3-glaucoma-trial-reaches-50-enrollment-milestone/2478999/Nicox announced that 50% of patients in the Mont Blanc NCX 470 phase 3 glaucoma clinical trial have now been randomized out of a target of 670, with topline results currently on track to be announced during Q2 2022. “We have been successful in maintaining a good recruitment rate in the Mon